Skip to content
Precision for Medicine
Contact Us
ring-the-bel-3l

Life-changing therapies
without a lifetime of
development

Precision for Medicine solves the most complex clinical development challenges to bring innovative therapies to patients. Contact Us

No one who is working to help patients in need should be subjected to unnecessary delays during clinical development and commercialization. Precision’s integrated capabilities, responsive operations and deep scientific expertise are helping life science innovators accelerate research and development while reducing cost and increasing the probability of approval.

Specialized capabilities for every stage of clinical development

Leverage an integrated infrastructure that reduces the inefficiencies inherent in complex development. Integrate lab and trial execution to increase speed to market. Precision brings a holistic view to your program's unique needs.

  • Discover Explore
    clinical-trial-support

    Global CRO
    Services

    Award-winning CRO with deep oncology and rare disease expertise

    Explore
  • Discover Explore
    specialty-lab-services

    Global Laboratory
    Services

    Exceptional translational and biomarker sciences with global clinical logistics services

    Explore
  • Discover Optimize early phase development
    Optimize early phase development

    Optimize early phase development

    How can you successfully navigate the complexities of early phase development? Integrated clinical and laboratory sciences capabilities are vital. Over 25 years of experience in early oncology development helps anticipate and mitigate a diverse set of risks, including complicated kitting and sample management.

    Discover
  • Discover Maximize late phase development
    Maximize late phase development

    Maximize late phase development

    Congratulations if you are entering late phase development. Now you’ll need a partner that can recruit patients most likely to respond to treatment, manage complex protocols, anticipate global regulatory requirements, enable manufacturing, support commercial viability and more. Let us drive your innovation to market and empower access for patients.

    Discover
human-

Trusted partner to leading innovators in oncology and rare disease

Clinical development is growing more complicated. Progress can hinge on the ability to navigate a shifting pathway to approval. Your path may be unique from those who have gone before, but our experience will help inform success. Precision is a leader in oncology and rare disease research. Our deep experience in complex indications accelerates the ability to reach key milestones, drive positive outcomes and most importantly, help patients get access to innovative treatments.

Contact us
70 of clinical trials are in oncology
2500 clinical trial and lab projects
5 specialty labs in the US and Europe
30 in investments raised for biotech in the last 5 years
CRO Winner Badge@2x

Winner of the 2025 Fierce Biotech CRO Award for Innovative Solutions in Drug Development

Precision is dedicated to operational excellence and our collaborative approach to tackling complex challenges in oncology and rare disease research.

This recognition highlights our successful rescue of a high-risk hematology-oncology trial, where we conducted a full operational and data gap analysis, rebuilt sponsor alignment through proactive collaboration, implemented centralized patient-level data monitoring, and developed custom tracking systems to accelerate regulatory and startup activities.

We’re proud to help advance critical therapies and grateful to the sponsors, investigators, and teams who make this work possible.

Read Press Release

Deep experience with debilitating disease and unique modalities

Like you, we understand that there’s a patient throughout the development pathway. Supporting our partners to bring innovative treatments to patients is our purpose. Leverage our experience in these therapeutic areas.

Oncology Explore Rare Diseases Explore Autoimmune Explore Gene Therapy Explore Cell Therapy Explore

  • People first and patient-focused

    One of our core values is service. Not just to our clients but to our communities. Volunteering at hospitals, supporting healthcare-related fund raisers and partnering with nonprofit organizations is an integral part of our culture. In doing so, we raise awareness of many life-altering diseases and our team gets closer to the actual patients that can be impacted by our work. 

  • People first and patient-focused

    One of our core values is service. Not just to our clients but to our communities. Volunteering at hospitals, supporting healthcare-related fund raisers and partnering with nonprofit organizations is an integral part of our culture. In doing so, we raise awareness of many life-altering diseases and our team gets closer to the actual patients that can be impacted by our work. 

  • People first and patient-focused

    One of our core values is service. Not just to our clients but to our communities. Volunteering at hospitals, supporting healthcare-related fund raisers and partnering with nonprofit organizations is an integral part of our culture. In doing so, we raise awareness of many life-altering diseases and our team gets closer to the actual patients that can be impacted by our work. 

Insights for the greater good

We feel privileged to work in an industry that can change lives. When knowledge is shared, it is amplified. Expanding our collective intelligence can bring remedies to market faster. 

Explore More
Read: Why Global Oncology Evidence May Not Support U.S. Regulatory Approval Why Global Oncology Evidence May Not Support U.S. Regulatory Approval

Clinical Trials - Regulatory

Why Global Oncology Evidence May Not Support U.S. Regulatory Approval

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=167363064857, hs_child_table_id=0, hs_updated_at=1719905898183, hs_published_at=1785476963368, description=Industry-leading oncologist and demonstrated medical leader in precision medicine, novel trial design and innovative regulatory initiatives designed to expedite drug approvals. Draws on nearly a decade leading oncology and rare disease programs at the FDA. Former fellow at the National Cancer Institute and frequent featured speaker at ASCO and AACR. CDER technical authority on oncologic drug and biological products for thoracic and head and neck malignancies, neurologic tumors, pediatric solid tumors and rare tumors., avatar=Image{width=553,height=580,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Harpreet-Singh2.png',altText='Harpreet-Singh2',fileId=171747124346}, linkedin=https://www.linkedin.com/in/harpreetsinghmd/, team=[{id=163072475007, name='Precision for Medicine Leadership'}], lastname=Singh, MD, hs_initial_published_at=1715692570942, hs_created_by_user_id=2737751, hs_created_at=1715692477118, hs_is_edited=false, hs_deleted_at=0, name=Harpreet, job=Chief Medical Officer, slug=harpreet-singh, hs_updated_by_user_id=65160865}, second={}, third={}})
  • Harpreet Singh, MD avatar

    Harpreet Singh, MD
Discover
Read: Early-Phase Oncology Trials in Ireland: Why START Dublin Is a High-Performing Site for Sponsors Early-Phase Oncology Trials in Ireland: Why START Dublin Is a High-Performing Site for Sponsors

Clinical Trials

Early-Phase Oncology Trials in Ireland: Why START Dublin Is a High-Performing Site for Sponsors

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=164713188870, hs_child_table_id=0, hs_updated_at=1754641424769, hs_published_at=1785476963368, description=Deana Demjen is Director of the Precision Site Network, bringing nearly 20 years of clinical research to the role. Most of her previous experience has been in feasibility and site-identification. She has been covering a wide range of therapeutic areas, but her main focus are rare diseases where she is an acting subject matter expert. She is responsible for relationships with PSN sites as well as the maintenance and expansion of the network., avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/Deana-Demjen-1.png',altText='Deana-Demjen-1',fileId=194123711869}, lastname=Demjen, hs_initial_published_at=1713363230550, hs_created_by_user_id=5166971, hs_created_at=1713363112834, hs_is_edited=false, hs_deleted_at=0, name=Deana, job=Director of PSN, slug=deana-demjen, hs_updated_by_user_id=65160865}, second={}, third={}})
  • Deana Demjen avatar

    Deana Demjen
Discover
Read: Receptor Occupancy in the Era of Multispecific Therapeutics Receptor Occupancy in the Era of Multispecific Therapeutics

Translational Research - Lab Services

Receptor Occupancy in the Era of Multispecific Therapeutics

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778875, hs_child_table_id=0, hs_updated_at=1716454216458, hs_published_at=1785476963368, description=Pharma industry veteran and expert at biomarker-driven clinical trial design and execution. Leader of biomarker and drug development programs for pharmaceutical and diagnostics companies, as well as the National Institutes of Health. Spearheaded the discovery of pharmacodynamic biomarkers and novel targets for inflammatory disease therapy., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Deb%20Phippard.webp',altText='Deb Phippard',fileId=165892372605}, linkedin=https://www.linkedin.com/in/deb-phippard-103b54, team=[{id=163072475007, name='Precision for Medicine Leadership'}], hs_name=, hs_path=, lastname=Phippard, PhD, hs_initial_published_at=1775839468505, hs_created_at=1709645745106, hs_is_edited=false, hs_deleted_at=0, name=Deborah, job= Chief Scientific Officer, slug=deborah-phippard, email=, hs_updated_by_user_id=65160865}, second={hs_id=218178874459, hs_child_table_id=0, hs_updated_at=1785241362455, hs_published_at=1785476963368, description=Jenny Zilberberg has more than 20 years of combined experience across academia and biotechnology, with expertise in translational immunology, cancer immunotherapy, and biomarker strategy. Most recently, she served as Head of Research at Imvax, where she led preclinical development and biomarker activities for the company’s immunotherapy platform and lead glioblastoma program. At Precision, Jenny partners with sponsors to design and implement biomarker and bioanalytical solutions that support clinical development across oncology and autoimmune diseases., avatar=Image{width=480,height=480,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/JennyZilberberg.jpeg',altText='JennyZilberberg',fileId=218182303073}, lastname=Zilberberg, hs_initial_published_at=1785241367324, hs_created_by_user_id=65712240, hs_created_at=1785241302354, hs_is_edited=false, hs_deleted_at=0, name=Jenny, job=Vice President, Scientific Strategy, slug=Jenny-zilberberg, hs_updated_by_user_id=65160865}, third={}})
  • Deborah P. avatar

    Deborah P.
  • Jenny Z. avatar

    Jenny Z.
Discover